Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial.
暂无分享,去创建一个
P. Moreau | X. Leleu | C. Touzeau | T. Facon | M. Attal | M. Roussel | C. Chaleteix | M. Tiab | C. Hulin | D. Caillot | L. Benboubker | B. Kolb